Gilead: Majority Of Certain Hep C Genotype 1 Patients Saw Viral Relapse

Date : 02/17/2012 @ 7:12AM
Source : Dow Jones News
Stock : Gilead Sciences, Inc. (MM) (GILD)
Quote : 73.74  -0.65 (-0.87%) @ 8:00PM

Gilead: Majority Of Certain Hep C Genotype 1 Patients Saw Viral Relapse

Gilead Sciences, Inc. (MM) (NASDAQ:GILD)
Historical Stock Chart

5 Years : From Jul 2012 to Jul 2017

Click Here for more Gilead Sciences, Inc. (MM) Charts.

Gilead Sciences Inc. (GILD) said the majority of certain hepatitis C genotype 1 patients it treated with its GS-7977 drug plus ribavirin had viral relapse within four weeks of completing 12 weeks of treatment, potentially putting into question the efficacy of the drug in some patients.

Shares were down 8.8% premarket at $50. As of Thursday's close, the stock has risen 34% since the start of 2012.

The biopharmaceutical last month completed its purchase of Pharmasset Inc. for more than $11 billion, in a deal expected to accelerate its hepatitis C drug pipeline. It said earlier this month that its GS-7977 drug--which it acquired in the deal--along with the older drug ribavirin, made hepatitis C undetectable after four weeks of treatment in all 10 patients with genotypes 2 and 3 treated. The trial was also the first to successfully eliminate interferon from the drug treatment. Interferon is a highly toxic, older hepatitis C drug with major side effects, and market watchers are keenly focused on drug developers finding ways to strip out that treatment from future hepatitis C regimens.

But, among eight genotype 1 patients treated, six experienced viral relapse. Two patients didn't, but they have only reached the two-week post-treatment time point. Those patients had a prior "null" response to an interferon-containing regimen.

"These data answer an important question about the use of GS-7977 and ribavirin for the treatment of genotype 1 null responder patients, suggesting that additional direct acting antivirals may be necessary to effectively treat this patient population," said Chief Scientific Officer Norbert Bischofberger. "We will continue to explore a number of therapeutic approaches to address this significant unmet medical need, including combinations with other oral antivirals."

Results from ongoing studies, including those involving genotype 1 treatment-native patients, will be released in the coming months.

Gilead earlier this month said its fourth-quarter earnings rose as the company's product sales continued to rise and it no longer booked deep reductions in royalties.

 
   -By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com 

Latest GILD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.